Followers | 44 |
Posts | 3130 |
Boards Moderated | 2 |
Alias Born | 01/18/2016 |
Sunday, January 02, 2022 11:40:33 AM
Recent CGTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:11:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/11/2024 08:06:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:44:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:13:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:13:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 12:12:08 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/19/2024 08:07:49 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:26 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/08/2024 09:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:21:33 PM
- Cognition Therapeutics CEO Issues Letter to Shareholders • GlobeNewswire Inc. • 01/04/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:02:07 PM
- Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens • GlobeNewswire Inc. • 11/16/2023 12:30:35 PM
- Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases • GlobeNewswire Inc. • 11/15/2023 12:30:48 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/13/2023 10:25:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 02:48:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 02:47:16 PM
- Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease • GlobeNewswire Inc. • 11/07/2023 12:30:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 11:45:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 11:41:02 AM
- Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 11:30:00 AM
- Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD • GlobeNewswire Inc. • 10/27/2023 11:30:15 AM
- Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD • GlobeNewswire Inc. • 10/24/2023 08:30:41 PM
- Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications • GlobeNewswire Inc. • 10/16/2023 11:30:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM